GM Advisory Group Inc. acquired a new stake in Teladoc Health Inc (NYSE:TDOC) during the first quarter, Holdings Channel.com reports. The institutional investor acquired 11,919 shares of the health services provider’s stock, valued at approximately $1,848,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Teladoc Health by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 621,774 shares of the health services provider’s stock worth $52,055,000 after acquiring an additional 15,025 shares in the last quarter. Champlain Investment Partners LLC raised its position in shares of Teladoc Health by 10.0% during the 4th quarter. Champlain Investment Partners LLC now owns 1,261,900 shares of the health services provider’s stock worth $105,646,000 after purchasing an additional 114,875 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Teladoc Health by 62.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 510,652 shares of the health services provider’s stock worth $42,752,000 after purchasing an additional 196,237 shares during the last quarter. Amalgamated Bank raised its position in shares of Teladoc Health by 5.9% during the 4th quarter. Amalgamated Bank now owns 13,170 shares of the health services provider’s stock worth $1,103,000 after purchasing an additional 739 shares during the last quarter. Finally, Capital World Investors raised its holdings in Teladoc Health by 56.5% in the 4th quarter. Capital World Investors now owns 230,000 shares of the health services provider’s stock valued at $19,256,000 after acquiring an additional 83,000 shares during the last quarter. 97.66% of the stock is currently owned by institutional investors.

In related news, SVP Andrew Turitz sold 14,122 shares of Teladoc Health stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $168.41, for a total transaction of $2,378,286.02. Following the completion of the transaction, the senior vice president now directly owns 12,552 shares of the company’s stock, valued at approximately $2,113,882.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Adam C. Vandervoort sold 22,516 shares of Teladoc Health stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $168.83, for a total transaction of $3,801,376.28. Following the transaction, the insider now directly owns 10,824 shares of the company’s stock, valued at $1,827,415.92. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 208,252 shares of company stock worth $35,286,838. 3.42% of the stock is owned by company insiders.

A number of research firms have weighed in on TDOC. Zacks Investment Research cut shares of Teladoc Health from a “buy” rating to a “hold” rating and set a $171.00 price objective for the company. in a research report on Thursday, May 28th. Cantor Fitzgerald increased their price objective on shares of Teladoc Health from $145.00 to $165.00 and gave the stock a “neutral” rating in a research note on Thursday, April 30th. Credit Suisse Group increased their price objective on shares of Teladoc Health from $152.00 to $165.00 and gave the stock a “neutral” rating in a research note on Thursday, April 30th. Royal Bank of Canada restated an “outperform” rating and issued a $200.00 price target on shares of Teladoc Health in a research note on Wednesday, May 27th. Finally, Bank of America raised their price target on shares of Teladoc Health from $106.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, February 27th. Fifteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $161.25.

Shares of Teladoc Health stock traded down $5.54 during trading on Wednesday, hitting $164.33. 1,890,651 shares of the company’s stock traded hands, compared to its average volume of 2,934,437. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.14 and a quick ratio of 6.14. The firm’s fifty day moving average price is $175.61 and its 200 day moving average price is $123.60. Teladoc Health Inc has a twelve month low of $53.46 and a twelve month high of $203.85. The company has a market cap of $12.93 billion, a PE ratio of -121.67 and a beta of 0.44.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, April 29th. The health services provider reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Teladoc Health had a negative net margin of 16.24% and a negative return on equity of 10.60%. The business had revenue of $180.80 million for the quarter, compared to analyst estimates of $180.64 million. During the same quarter last year, the firm posted ($0.43) earnings per share. Teladoc Health’s revenue was up 40.6% on a year-over-year basis. As a group, equities research analysts anticipate that Teladoc Health Inc will post -1.12 earnings per share for the current year.

Teladoc Health Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Read More: Trading based on a resistance level

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health Inc (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.